arrow
M

Mingjia Li

The Ohio State University
H指数:15
被引数:898

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome–immune cell signatures

质子泵抑制剂对免疫疗法的影响受先前化疗的调节,并与肠道微生物组–免疫细胞特征相关联

2026-03-090
OAAI
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy

免疫相关和非免疫相关住院对接受一线免疫治疗的非小细胞肺癌患者生存的影响

2025-11-070
PRE
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors

早期淋巴细胞/单核细胞比值的变化作为免疫检查点抑制剂治疗晚期癌症患者时预测总生存期的预后标志物

2025-10-010
PRE
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

肺大细胞神经内分泌癌的整合分子与临床特征分析

2025-08-190
OA
Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based Therapies

早期急性肾损伤及其与接受一线免疫疗法治疗的转移性非小细胞肺癌患者生存期的关联

2025-07-280
OAAI
Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Non-Small Cell Lung Cancer

简报:对于不可切除的局部晚期非小细胞肺癌,在同步放化疗后接受度鲁瓦鲁单抗治疗出现中枢神经系统转移的情况。

2025-07-050
PREAI
Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients

免疫检查点抑制剂治疗慢性阻塞性肺疾病合并肺癌患者的疗效评价

2025-02-210
OAAI
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer

肺癌患者治疗前胸部影像学检查与免疫检查点抑制剂肺炎的关系

2023-11-015
OA
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

KRASG12C抑制剂在晚期NSCLC中的疗效和作用

2023-04-1765
OA
SAFETY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITORS (ICI) IN PATIENTS LIVING WITH HIV (PLWH) AND METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A MATCHED COHORT STUDY FROM THE INTERNATIONAL CATCH-IT CONSORTIUM
2022-11-070
OA
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy

血清白蛋白: 免疫检查点抑制剂单药治疗而非化学免疫治疗获益的早期预后指标

2022-06-0121
OAAI
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer

晚期癌症老年患者的检查点抑制剂免疫疗法毒性与总生存期

2021-06-0125
OA
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications
2020-05-0646
OAAI